l General Information |
Product Name | Mubritinib |
General description | Mubritinib is a potent inhibitor of HER2/ErbB2. |
Synonym | 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole; TAK 165;TAK-165 |
Purity | ≥98%(HPLC) | CAS Number | 366017-09-6 |
Formula | C25H23F3N4O2 | Molecular Weight | 468.48 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or grayish white solid |
Solubility(25℃) | DMSO | ~10mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Mubritinib (TAK-165) is a potent and selective inhibitor of the human epidermal growth factor receptor 2 ErbB (HER2) tyrosine kinase. Mubritinib potently inhibits proliferation of cancer cell lines over- expressing ErbB2. |
Application | Mubritinib has been used in trials studying the treatment of Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm. |
l Packaging & Storage |
Packaging | 5mg; 25mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
